The double dose of Trelegy Ellipta, which was approved for asthma, not COPD, is making rapid progress for reimbursement listing in korea.

According to the pharmaceutical industry, GSK Korea has recently started reimbursement pricing negotiations with the National Health Insurance Service for its Trelegy 200 Ellipta (fluticasone furoate ·umeclidinium ·vilanterol).

On the 9th, Trelegy 200 Ellipta has successfully passed the Health Insurance Review and Assessment Service (HIRA)'s Drug Reimbursement Committee.

Therefore, industry eyes are on whether Trelegy Ellipta's reimbursement would be expanded to asthma in addition to its COPD indication.

Trelegy 200 Ell